Myopia Control Efficacy of Asymmetric Multipoint Defocus Technique Spectacle Lenses: One-Year Double-Masked Randomized Controlled Trial
- PMID: 40306584
- DOI: 10.1016/j.ophtha.2025.04.022
Myopia Control Efficacy of Asymmetric Multipoint Defocus Technique Spectacle Lenses: One-Year Double-Masked Randomized Controlled Trial
Abstract
Purpose: To evaluate the 12-month myopia control efficacy of an asymmetric multipoint defocus technique (AMDT) spectacle lens.
Design: Double-masked randomized controlled trial.
Participants: One hundred forty participants completed all visits (mean age, 10.6 ± 1.5 years; 50% female), with spherical equivalent refraction (SER) between -5.00 and -0.75 diopters (D), astigmatism of 1.50 D or less, and anisometropia of 1.50 D or less.
Methods: One hundred forty-four children 8 to 13 years of age with myopia of -0.75 D to -5.00 D recruited from 2 ophthalmic centers were randomized (1:1) to wear AMDT spectacle lenses or single-vision lenses (SVLs). Cycloplegic SER and axial length (AL) were measured at the baseline, 6-month, and 12-month visits. Adaptation and visual performance questionnaires were administered during the intervention.
Main outcome measures: The SER change after 1 year was the primary outcome, and the changes in AL, visual performance, and ocular parameters after 1 year were defined as secondary outcomes.
Results: After 12 months, the SVL group (n = 69) exhibited mean changes in SER and AL of -0.50 ± 0.06 D and 0.32 ± 0.02 mm, respectively, compared with -0.16 ± 0.06 D and 0.17 ± 0.02 mm (both P < 0.001) in the AMDT group (n = 71). Compared with the SVL group, participants in the AMDT group showed significantly less myopia progression by 0.39 D in SER (74%) and 0.17 mm in AL (51%) after adjustment for baseline age, baseline SER and AL, and ophthalmic center. The correlation between younger age and more rapid AL elongation was more pronounced in the SVL group (r = -0.68; P < 0.001) compared with the AMDT group (r = -0.37; P = 0.002). Thirty participants (42%) in the AMDT group displayed no SER progression after 1 year. No serious adverse events or persistent visual discomfort were observed.
Conclusions: Compared with SVLs, AMDT spectacle lenses significantly reduced SER and AL progression over 1 year, with a favorable safety profile and visual performance. The correlation between age and myopia progression was diminished after AMDT participants intervention, but not for SVLs.
Financial disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Keywords: Axial length; Myopia control; Myopic defocus; Spectacle lenses.
Copyright © 2025 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results.Ophthalmic Physiol Opt. 2025 Jun;45(4):1025-1035. doi: 10.1111/opo.13517. Epub 2025 Apr 29. Ophthalmic Physiol Opt. 2025. PMID: 40296784 Free PMC article. Clinical Trial.
-
Interventions for myopia control in children: a living systematic review and network meta-analysis.Cochrane Database Syst Rev. 2025 Feb 13;2(2):CD014758. doi: 10.1002/14651858.CD014758.pub3. Cochrane Database Syst Rev. 2025. PMID: 39945354
-
Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine.Br J Ophthalmol. 2025 Aug 20;109(9):1074-1080. doi: 10.1136/bjo-2024-326852. Br J Ophthalmol. 2025. PMID: 40345841 Clinical Trial.
-
Diversified Segmental Defocus Optimization Lenses With and Without Atropine for Myopia Prevention: A Randomized Clinical Trial.JAMA Ophthalmol. 2025 Aug 1;143(8):684-691. doi: 10.1001/jamaophthalmol.2025.2072. JAMA Ophthalmol. 2025. PMID: 40638107 Clinical Trial.
-
Interventions for myopia control in children: a living systematic review and network meta-analysis.Cochrane Database Syst Rev. 2023 Feb 16;2(2):CD014758. doi: 10.1002/14651858.CD014758.pub2. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2025 Feb 13;2:CD014758. doi: 10.1002/14651858.CD014758.pub3. PMID: 36809645 Free PMC article. Updated.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical